← Eichor
Study identifier: NCT06450873 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Condition: Estrogen Receptor-Positive Breast Carcinoma · HER2-Negative Breast Carcinoma  ·  Sponsor: Mayo Clinic

PhasePhase 2
Planned participants40
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Referral Office  ·  855-776-0015  ·  mayocliniccancerstudies@mayo.edu

Cancer Center Clinical Trials  ·  507-293-6386

Always discuss trial participation with your own doctor first.

Locations (1)

Mayo Clinic in ArizonaScottsdale, Arizona, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06450873